Real-World Evidence: Geriatric Cannabinoid Pharmacotherapy & Adverse Effect Incidence in Patients Aged 65+
Real-World Evidence: Geriatric Cannabinoid Pharmacotherapy & Adverse Effect Incidence in Patients Aged 65+
Clinical registry findings on cannabinoid tolerability, polypharmacy interactions, and falls/cognitive impairment incidence in geriatric cohorts managed under physician supervision. Derived from longitudinal physician evaluations across 81,008 unique clinical cohorts and 130,447 structured clinical follow-up encounters at CED Clinic.
Methodology & Observational Grounding
Unlike traditional pharmaceutical clinical trials that restrict inclusion criteria to single-diagnosis participants devoid of concurrent medications, the CED Clinic Real-World Evidence Registry captures the complex clinical reality of outpatient cannabinoid medicine. Patients in this cohort were systematically evaluated under board-certified physician supervision, with structured longitudinal tracking of symptom burden, medication de-escalation, adverse event incidence, and chemovar responsiveness.
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
“In patients aged 65 and older, real-world adverse events are overwhelmingly concentrated in unmonitored rapid-onset inhaled products. Conversely, slow-titration sublingual and oral formulations demonstrate excellent safety profiles with significant reductions in polypharmacy burden.”